Last reviewed · How we verify
Zunveyl (BENZGALANTAMINE)
Zunveyl works by enhancing communication between brain cells, specifically by stimulating cholinergic receptors.
At a glance
| Generic name | BENZGALANTAMINE |
|---|---|
| Sponsor | Alpha Cognition |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 2024 |
Mechanism of action
Although the etiology of cognitive impairment in Alzheimer's disease (AD) is not fully understood, it has been reported that acetylcholine-producing neurons degenerate in the brains of patients with Alzheimer's disease. The degree of this cholinergic loss has been correlated with degree of cognitive impairment and density of amyloid plaques (a neuropathological hallmark of Alzheimer's disease). ZUNVEYL is a prodrug of galantamine. Galantamine, a tertiary alkaloid, is a competitive and reversible inhibitor of acetylcholinesterase. While the precise mechanism of galantamine's action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. If this mechanism is correct, galantamine's effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact. Th
Approved indications
- mild to moderate dementia of the Alzheimer's type
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Dizziness
- Headache
- Decreased appetite
- Fatigue
- Depression
- Abdominal pain
- Decreased weight
- Bradycardia
- Tremor
Drug interactions
- anticholinergic medications
- succinylcholine
- other cholinesterase inhibitors
- similar neuromuscular blocking agents
- cholinergic agonists
- bethanechol
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zunveyl CI brief — competitive landscape report
- Zunveyl updates RSS · CI watch RSS
- Alpha Cognition portfolio CI